Market Place
Sourcing Support
Kintara Announces 1-For-35 Reverse Stock Split For Merger with TuHURA
16 Oct 2024 //
PR NEWSWIRE
Kintara Corrects Announcement On Reverse Stock Split Merger
16 Oct 2024 //
PR NEWSWIRE
Kintara Therapeutics Announces Correction On CVR Issuance
15 Oct 2024 //
PR NEWSWIRE
Kintara Therapeutics Announces Record Date For CVR Issuance
14 Oct 2024 //
PR NEWSWIRE
Kintara Therapeutics Announces Fiscal 2024 Results And Update
08 Oct 2024 //
PR NEWSWIRE
Kintara Adjourns Special Meeting of Stockholders To October 4
20 Sep 2024 //
PR NEWSWIRE
Kintara Urges Stockholders to Vote on Proposed Merger with TuHURA
18 Sep 2024 //
PR NEWSWIRE
Kintara Therapeutics Updates On Corporate And REM-001 Clinical Study
11 Sep 2024 //
PR NEWSWIRE
Kintara Sets Stockholder Meeting For TuHURA Biosciences Merger
09 Sep 2024 //
PR NEWSWIRE
Kintara And TuHURA Update On Corporate And Clinical Progress
01 Jul 2024 //
PR NEWSWIRE
Kintara Therapeutics Announces Fiscal 2024 Third Quarter Financial Results
14 May 2024 //
PR NEWSWIRE
Kintara Therapeutics and TuHURA Biosciences to Merge
03 Apr 2024 //
PR NEWSWIRE
Kintara Announces Expansion of Study to Include Patients on Pembrolizumab
27 Mar 2024 //
PR NEWSWIRE
Kintara Therapeutics Announces Fiscal 2024 Second Quarter Financial Results
14 Feb 2024 //
PR NEWSWIRE
Kintara Therapeutics Announces Review of Strategic Alternatives
07 Dec 2023 //
PR NEWSWIRE
Kintara Therapeutics Granted Extension by Nasdaq to Regain Compliance
05 Dec 2023 //
PR NEWSWIRE
Kintara Therapeutics Announces Fiscal 2024 First Quarter Financial Results
13 Nov 2023 //
PR NEWSWIRE
Kintara Therapeutics Announces Preliminary Topline Results From GBM AGILE Study
31 Oct 2023 //
PR NEWSWIRE
Kintara to Present at the 8th Annual Dawson James Small Cap Growth Conference
11 Oct 2023 //
PR NEWSWIRE
Kintara Therapeutics to Present at the LD Micro Main Event XVI Conference
02 Oct 2023 //
PR NEWSWIRE
Kintara Presents Case Studies of Glioblastoma Patients Treated with VAL-083
25 Sep 2023 //
PR NEWSWIRE
Kintara Therapeutics Announces Fiscal 2023 Year Financial Results
18 Sep 2023 //
PR NEWSWIRE
Kintara to Present at the 2023 European Association for Annual Meeting
05 Sep 2023 //
PR NEWSWIRE
Kintara Therapeutics to Host Virtual KOL Event on VAL-083
17 Aug 2023 //
PR NEWSWIRE
Kintara Awarded $2.0 M NIH SBIR Grant to Support REM-001
28 Jun 2023 //
PR NEWSWIRE
Kintara Therapeutics to Participate in the Maxim Group Virtual Conference
16 Jun 2023 //
PR NEWSWIRE
Kintara Therapeutics to Present at the Sidoti Micro-Cap Virtual Conference
08 May 2023 //
PR NEWSWIRE
Kintara Therapeutics to Present at the Aegis Capital Virtual Conference
01 May 2023 //
PR NEWSWIRE
Kintara to Present Posters at 2023 American Association for Research Meeting
15 Mar 2023 //
PR NEWSWIRE
Kintara Scheduled to Present at Two Conferences the Week of March 13, 2023
10 Mar 2023 //
PR NEWSWIRE
Kintara Therapeutics Announces Fiscal 2023 Second Quarter Financial Results
14 Feb 2023 //
PR NEWSWIRE
Kintara Therapeutics to Present at the 2023 BIO CEO & Investor Conference
30 Jan 2023 //
PR NEWSWIRE
Kintara to Present at Biotech Showcase Conference on January 10, 2023
09 Jan 2023 //
PR NEWSWIRE
Kintara Receives Orphan Drug Designation for VAL-083 for Treatment of DIPG
16 Dec 2022 //
BIOSPACE
Kintara Therapeutics to Participate at RHK Capital Disruptive Growth Conference
01 Dec 2022 //
PRESS RELEASE
Kintara Regains Compliance with Nasdaq Minimum Bid Price Requirement
30 Nov 2022 //
PRESS RELEASE
Kintara Therapeutics Regains Compliance with Nasdaq Minimum Bid Price
30 Nov 2022 //
PRNEWSWIRE
Kintara Therapeutics Granted Fast Track Designation from FDA for REM-001
28 Nov 2022 //
KINTARA
FDA Fast Track designation for photodynamic cancer therapy
28 Nov 2022 //
EUROPEANPHARMACEUTICALREVIEW
Kintara Presents 3 Posters at the 2022 Society for Neuro-Oncology Annual Meeting
18 Nov 2022 //
PRNEWSWIRE
Kintara Announces One-for-Fifty Reverse Stock Split
11 Nov 2022 //
PRESS RELEASE
Kintara Therapeutics Announces Fiscal 2023 First Quarter Financial Results
09 Nov 2022 //
PRNEWSWIRE
Kintara`s Three Abstracts Have Been Accepted for Neuro-Oncology Annual Meeting
08 Sep 2022 //
PRNEWSWIRE
Kintara Tx Receives Study May Proceed Letter from the FDA for REM-001 for CMBC
09 Aug 2022 //
PRNEWSWIRE
Kintara Enters Equity Purchase Agreement for Upto $20M with Lincoln Park Capital
03 Aug 2022 //
PRNEWSWIRE
FDA Grants FTD to Kintara`s VAL-083 for Newly-Diagnosed Glioblastoma
15 Jun 2022 //
PRNEWSWIRE
Kintara Therapeutics to Present at the JMP Securities Life Sciences Conference
10 Jun 2022 //
PRNEWSWIRE
Kintara Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement
03 Jun 2022 //
PRNEWSWIRE
Kintara activates first European site of Phase II/III glioblastoma trial
30 May 2022 //
CLINICALTRIALSARENA
Kintara`s Site Activation in Switzerland in GCAR PII/III Trial for Glioblastoma
27 May 2022 //
PRNEWSWIRE
Kintara Therapeutics Announces Fiscal 2022 Third Quarter Financial Results
13 May 2022 //
PRNEWSWIRE
Kintara Announces Closing of $8.6M Registered Direct Offering
14 Apr 2022 //
PRNEWSWIRE
Kintara Announces $8.6M Registered Direct Offering
12 Apr 2022 //
PRNEWSWIRE
Kintara Therapeutics Presents Data at AACR
11 Apr 2022 //
PRNEWSWIRE
Kintara Tx says Data Presentation at the 2022 AACR
15 Mar 2022 //
PRNEWSWIRE
Kintara Tx Announces Fiscal 2022 Q2 Financial Results; Provides Corporate Update
11 Feb 2022 //
PRNEWSWIRE
Kintara Tx to Present at BIO CEO & Investor Conference on February 15, 2022
04 Feb 2022 //
PRNEWSWIRE
Kintara Tx Bags Issuance of New US Patent Related to VAL-083 and MGMT Resistance
03 Feb 2022 //
PRNEWSWIRE
Kintara Presents Updates on Two Phase 2 Clinical Studies
18 Nov 2021 //
PRNEWSWIRE
Kintara Announces Fiscal 2022 Q1 Financial Results and Provides Corporate Update
15 Nov 2021 //
PRNEWSWIRE
